ALNYLAM PHARMACEUTICALS, INC.: net_income
| Value | {"amount": -858281000, "concept": "us-gaap:NetIncomeLoss", "currency": "USD"} |
|---|---|
| Period | 2020-01-01 – 2020-12-31 |
| Status | current |
| Entity | ALNYLAM PHARMACEUTICALS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T11:51:50.761763+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/2c0de981-1544-4559-90fa-3c172dff6c09
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001178670-21-000010Retrieved: 2026-08-19T11:51:50.761763+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001178670/net-income/2020-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/2c0de981-1544-4559-90fa-3c172dff6c09
History
- no predecessors — first report